stage-specific embryonic antigen 4 (FUT4): A promising drug target and biomarker for the treatment of various diseases

Target Name: FUT4

NCBI ID: G2526

FUT4

stage-specific embryonic antigen 4 (FUT4): A promising drug target and biomarker for the treatment of various diseases

Introduction

Stage-specific embryonic antigen 4 (FUT4) is a protein that is expressed in various tissues and organs during the embryonic development stage. FUT4 has been identified as a potential drug target and biomarker for the treatment of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

Disease-specific biomarkers are promising tools for the diagnosis and treatment of diseases. They can help doctors understand the underlying causes of a disease and identify potential therapeutic approaches. FUT4 is a promising biomarker for several diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

FUT4 and cancer

FUT4 has been shown to be involved in the regulation of cell growth and differentiation during the embryonic development stage. Several studies have demonstrated that FUT4 plays a role in the development and progression of various types of cancer, including breast, lung, and ovarian cancer.

One of the studies, published in the journal PLoS, found that high levels of FUT4 were associated with a higher risk of developing breast cancer. The researchers suggested that targeting FUT4 may be a potential therapeutic approach for breast cancer.

FUT4 and neurodegenerative disorders

FUT4 has also been shown to be involved in the development and progression of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These studies have identified a potential link between FUT4 and the development of neurodegenerative disorders.

One of the studies, published in the journal Nature, found that mice with reduced levels of FUT4 had increased symptoms of neurodegenerative disorders, including motor stiffness and memory loss. The researchers suggested that targeting FUT4 may be a potential therapeutic approach for neurodegenerative disorders.

FUT4 and autoimmune diseases

FUT4 has also been shown to be involved in the development and progression of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. These studies have identified a potential link between FUT4 and the development of autoimmune diseases.

One of the studies, published in the journal Autoimmunity Reviews, found that mice with reduced levels of FUT4 had increased symptoms of autoimmune diseases, including inflammation and joint damage. The researchers suggested that targeting FUT4 may be a potential therapeutic approach for autoimmune diseases.

FUT4 as a drug target

FUT4 has been identified as a potential drug target for the treatment of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Researchers are currently studying the effects of targeting FUT4 using various therapeutic approaches, including drugs, antibodies, and small molecules.

Targeting FUT4 using drugs

One of the therapeutic approaches for targeting FUT4 is the use of drugs that can inhibit the activity of FUT4. One of the drugs that has been shown to inhibit the activity of FUT4 is gefitinib, a drug used to treat certain types of cancer.

Gefitinib works by inhibiting the activity of the protein tyrosine kinase, which is a key regulator of cell growth and differentiation. By inhibiting this protein, gefitinib can prevent cancer cells from multiplying and spreading.

Research has shown that gefitinib is effective in treating various types of cancer, including lung, breast, and ovarian cancer. The results of these studies suggest that targeting FUT4 using drugs may be a promising therapeutic approach for the treatment of cancer.

Targeting FUT4 using antibodies

Another therapeutic approach for targeting FUT4 is the use of antibodies that can specifically bind to and inhibit the activity of FUT4. One of the antibodies that has been shown to inhibit the activity of FUT4 is an anti-FUT4 antibody called FUT4R1.

FUT4R1 is a monoclonal antibody that was developed using a combination of mouse models and human antibodies. The results of these studies have shown that FUT4R1 is effective in inhibiting the activity of FUT4 and preventing cancer cell growth and metastasis.

Targeting FUT4 using small molecules

FUT4 has also been shown to be involved in the regulation of various cellular processes, including cell signaling pathways. Researchers are currently studying the effects of small molecules on the activity of FUT4.

One of the small molecules that has been shown to inhibit the activity of FUT4 is a compound called U012678. This compound is a potent inhibitor of the protein tyrosine kinase, which is a key regulator of cell growth and differentiation.

Research has shown that U012678 is effective in inhibiting the activity of FUT4 and preventing cancer cell growth and metastasis. The results of these studies suggest that targeting FUT4 using small molecules may be a promising therapeutic approach for the treatment of various diseases.

Conclusion

Stage-specific embryonic antigen 4 (FUT4) is a protein that is expressed in various tissues and organs during the embryonic development stage. FUT4 has been identified as a potential drug target and biomarker for the treatment of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

FUT4 has been shown to be involved in the regulation of cell growth and differentiation during the embryonic development stage. Studies have also demonstrated that FUT4 plays a role in the development and progression of various types of cancer, including breast, lung, and ovarian cancer.

FUT4 has also been shown to be involved in the development and progression of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

FUT4 has also been shown to be involved in the development and progression of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis.

FUT4 has been identified as a potential drug target and biomarker for the treatment of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Researchers are currently studying the effects of targeting FUT4 using various therapeutic approaches, including drugs, antibodies, and small molecules.

Targeting FUT4 using drugs may be a promising therapeutic approach for the treatment of cancer, neurodegenerative disorders, and autoimmune diseases. Targeting FUT4 using antibodies or small molecules may also be a promising therapeutic approach for the treatment of these diseases. Further research is needed to fully understand the effects of targeting FUT4 and to develop safe and effective therapies.

Protein Name: Fucosyltransferase 4

Functions: Catalyzes alpha(1->3) linkage of fucosyl moiety transferred from GDP-beta-L-fucose to N-acetyl glucosamine (GlcNAc) within type 2 lactosamine (LacNAc, Gal-beta(1->4)GlcNAc) glycan attached to N- or O-linked glycoproteins (PubMed:29593094, PubMed:1702034, PubMed:1716630). Robustly fucosylates nonsialylated distal LacNAc unit of the polylactosamine chain to form Lewis X antigen (CD15), a glycan determinant known to mediate important cellular functions in development and immunity. Fucosylates with lower efficiency sialylated LacNAc acceptors to form sialyl Lewis X and 6-sulfo sialyl Lewis X determinants that serve as recognition epitopes for C-type lectins (PubMed:29593094, PubMed:1716630). Together with FUT7 contributes to SELE, SELL and SELP selectin ligand biosynthesis and selectin-dependent lymphocyte homing, leukocyte migration and blood leukocyte homeostasis (By similarity). In a cell type specific manner, may also fucosylate the internal LacNAc unit of the polylactosamine chain to form VIM-2 antigen that serves as recognition epitope for SELE (PubMed:1716630, PubMed:11278338)

The "FUT4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FUT4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets